RP-6306 is under clinical development by Repare Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RP-6306’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RP-6306 overview

RP-6306 is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, ovarian, breast, hepatocellular, head and neck squamous cell carcinoma, endometrial cancer, gastroesophageal cancer, fallopian tube cancer, peritoneal cancer, uterine cancer, triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma, non-small cell lung cancer and esophageal cancer. It is administered through oral route. It acts by targeting Cyclin E 1 (CCNE1) and PKMYT1.

Repare Therapeutics overview

Repare Therapeutics is a precision oncology company that develops novel therapeutics targeting specific vulnerabilities of tumor cells. The company’s pipeline products include RP-3500 to treat genetically defined cancers, PKMYT1 Inhibitor RP-6306

For a complete picture of RP-6306’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.